Evidence & regulatory context
- Mechanism
- Cyclodextrin cholesterol-sequestering agent. ChEMBL entry is the parent betadex (beta-cyclodextrin); the therapy is the methylated derivative methyl-beta-cyclodextrin.
- Target
- Not recorded
- Injury models
- Other
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Preclinical/no trial
- ChEMBL max phase
- 3 / 4 (development scale, not regulatory approval)
- Synonyms
- Beta-cyclodextrin; Betadex; Kleptose
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MixedOther
Model: Mouse model of acute respiratory distress syndrome; human acute bronchiolitis samples
Methyl-beta-cyclodextrin restored surfactant surface tension function to normal in both human bronchiolitis and ARDS mouse samples, and showed anti-inflammatory effects. Surfactant inhibition was attributed to elevated cholesterol and a cholesterol with oxidised phospholipid interaction.
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.
